מתוך medicontext.co.il
WESTPORT, CT (Reuters Health) – There are no significant differences in glycemic control, reported hypoglycemic events, or quality of life between type 1 diabetic patients treated with continuous subcutaneous insulin infusion (CSII) and those treated with multiple daily insulin injection (MDI), according to a report in the October issue of Diabetes Care.
Dr. Bernard Zinman, of Mount Sinai Hospital in Toronto, and colleagues conducted a randomized, controlled trial of 27 type 1 diabetic patients who received insulin lispro with a CSII (n = 13) or MDI (n = 14) regimen. Glycemic control (HbA1c level) and reported hypoglycemic events were measured monthly for 9 months. Quality of life was assessed at 9 months.
Patients in the CSII group had a mean HbA1c at baseline of 7.73%, compared with 8.16% for patients in the MDI group. Both groups of patients had significant decreases in HbA1c levels at all time points, the team explains.
Overall, the investigators "found no differences in outcome between the two [treatment] groups in terms of HbA1c levels, hypoglycemic events, or quality of life measured using the Diabetes Quality of Life questionnaire."
"The findings of our study indicate that the choice of the method of intensive insulin therapy should be a matter of personal preference," Dr. Zinman and colleagues conclude. "It is important for all patients with type 1 diabetes to have the option to select the therapy that is most suitable for them."
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!